Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jianmin Wang
Observed names:
J Wang,
J. WANG,
J. Wang
Institution:
RTI Health Solutions
Observed institution:
RTI Health Solutions
OpenAlex ID:
A5046008232
Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome
2008
·
A. W. MANGEL
, J. D. BORNSTEIN
, et al.
·
Alimentary Pharmacology & Therapeutics
·
140
PDF
Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting
2007
·
M. J. Naslund
, A. W. Gilsenan
, et al.
·
International Journal of Clinical Practice
·
46
Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom
2007
·
Annalisa Rubino
, Matthew D. Rousculp
, et al.
·
Primary care diabetes
·
42
Diagnosed diabetic retinopathy in France, Italy, Spain, and the United Kingdom
2007
·
A. Rubino
, M.D. Rousculp
, et al.
·
Primary care diabetes
·
36
A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
2011
·
J Wang
, Z Zhao
, et al.
·
British Journal of Cancer
·
33
PDF
Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
2013
·
B Sherrill
, J Wang
, et al.
·
British Journal of Cancer
·
30
PDF
Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer
2016
·
Jianmin Wang
, Guy Hechmati
, et al.
·
Current Medical Research and Opinion
·
6
Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in the PRIME trial.
2015
·
Jianmin Wang
, Jun Dong
, et al.
·
Journal of Clinical Oncology
·
4
Pcn86 a Q-twist Analysis Comparing Panitumumab Plus Best Supportive Care (bsc) With Bsc Alone in Patients With Wild-type Kras Metastatic Colorectal Cancer
2011
·
J. Wang
, Z. Zhao
, et al.
·
Value in Health
·
3
The PRIME trial: Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone.
2015
·
Jianmin Wang
, Jun Dong
, et al.
·
Journal of Clinical Oncology
·
2
Evaluation Of Matching-Adjusted Indirect Comparison Implemented By A Resampling Method
2015
·
J. Wang
, D. Odom
, et al.
·
Value in Health
·
1
Practical issues when conducting network meta-analyses with a limited number of studies
2014
·
D. Odom
, C. Chirila
, et al.
·
Value in Health
·
1
PDF
PCN3 Quality-Adjusted Survival in Patients With Wild-Type (WT) KRASs Metastatic Colorectal Cancer (mCRC) Receiving First-Line Therapy With Panitumumab Plus FOLFOX Versus FOLFOX Alone
2012
·
J. Wang
, Z Zhao
, et al.
·
Value in Health
·
1
1499: The Prevalence of LUTS and Prostate Enlargement in the Primary Care Setting
2007
·
Michael Naslund
, Alicia Gilsenan
, et al.
·
The Journal of Urology
·
1
ASPECCT: panitumumab versus cetuximab for colorectal cancer
2014
·
PE Goss
, Lee-Bychkovsky Bl
, et al.
Quality-Adjusted Survival in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Receiving First-Line Therapy with Panitumumab Plus Folfox Versus Folfox Alone
2012
·
J. Wang
, Z. Zhao
, et al.
·
Annals of Oncology
Puk20 Improvements in Health-related Quality of Life With Fesoterodine: King's Health Questionnaire Item Analysis
2008
·
V Khullar
, C Kelleher
, et al.
·
Value in Health
PDF
Po4 Estimating Quality-adjusted Time Without Symptoms Ortoxicity Using a Multivariate Failure Time Regression Model
2005
·
J Wang
, B Sherrill
, et al.
·
Value in Health
Show more works
View as search
Works count:
18
Citation count:
346
H-index:
6
I10-index:
6
Year
Topic
Type